Glucose Health, Inc. USPTO
Patent Filing Asserts First Use of Nutritional Composition
Underlying GLUCODOWN®
BENTONVILLE, AR --
December 28, 2021 -- InvestorsHub NewsWire -- Glucose Health, Inc.
(OTC:
"GLUC") ("Company") is pleased to advise that a patent
application for "Compositions and Methods for Metabolic Health" was
filed with the United States Trademark and Patent Office (USPTO) on
December 23, 2021, on behalf of the Company.
The patent filing
discloses a composition of the combination of resistant dextrin,
corosolic acid and chromium picolinate, in measures for maintaining
and improving health by attenuating post-prandial glycemic and
lipid increases and/or lowering levels of plasma glucose and
lipids. The composition disclosed is the nutritional foundation of
the Company's GLUCODOWN® products.
The purpose of the
USPTO filing is to assert Glucose Health, Inc.'s claims and rights
for the way in which the composition may be used. Prior to filing,
a worldwide patent search was commissioned, which indicated the
composition disclosed by the Company is its first use, in the
context of a nutritional product, in the world.
About Glucose Health, Inc. (OTC: GLUC)
With its
focus on creating delicious beverages nutritionally
appropriate1 for
the nation's 100+ million2 pre
and Type-2 diabetics, Glucose Health, Inc., the manufacturer of
GLUCODOWN®, is uniquely positioned among emerging beverage
companies. Introduced in the third quarter of 2018, the Company's
GLUCODOWN® is the market leading brand for new & innovative,
diabetic friendly & delicious, beverages. Glucose Health, Inc.
is a publicly traded company with the ticker symbol OTC:
GLUC.
To buy GLUCODOWN® visit our Amazon Store at
www.amazon.com/glucodown
Like us on Facebook at www.facebook.com/glucodown
For more GLUC information visit www.glucosehealthinc.com
1
For
citations visit www.glucodown.com/clinical-data
2
National Diabetes Statistics Review, 2020; Centers for Disease
Control and Prevention, Department of Health and Human
Services
This news release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and while Glucose
Health, Inc. is not subject to the 1934 Securities and Exchange
Act, contains forward-looking statements within the meaning Section
21E of the Securities and Exchange Act of 1934, as amended.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,
"possible," "probable, "believes," "seeks," "may, "will, "should,"
"could" or the negative of such terms or other similar expressions.
Actual results may differ materially from those set forth in this
release due to the risks and uncertainties inherent in the
Company's business. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and the Company
undertakes no obligation to revise or update this release to
reflect events or circumstances after the date hereof.
Contact:
Murray
Fleming
Glucose Health,
Inc.
info@glucosehealthinc.com
(479)
802-3827